Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Effects of Video-Based Education on Symptom Management Self-Efficacy and Quality of Life in Women Receiving Chemotherapy for Breast Cancer

10. november 2026 oppdatert av: Antalya Bilim University

The Effect of a Video-Based Educational Intervention on Symptom Management Self-Efficacy and Quality of Life in Women With Breast Cancer Receiving Chemotherapy

This study is designed as a randomized controlled trial to evaluate the effect of a video-based educational intervention on symptom management self-efficacy and quality of life in women diagnosed with breast cancer who are receiving chemotherapy. The study will be conducted at the Day Chemotherapy Unit of Akdeniz University Hospital. The study sample will consist of female patients diagnosed with breast cancer who meet the inclusion criteria and consent to participate. Participants will be divided into two groups: an intervention group and a control group.

Studieoversikt

Status

Har ikke rekruttert ennå

Forhold

Detaljert beskrivelse

This study is designed as a randomized controlled trial to evaluate the impact of a video-based educational intervention on self-efficacy for symptom management and quality of life in women diagnosed with breast cancer who are undergoing chemotherapy. The study will be conducted at the Day Chemotherapy Unit of Akdeniz University Hospital. The study sample will consist of women diagnosed with breast cancer who meet the inclusion criteria and consent to participate. Participants will be assigned to either an intervention group or a control group. The sample size was calculated using the G*Power 3.1.9 software, determining that a minimum of 72 participants-36 in each group-are required. Accounting for potential attrition, the study is planned to include a total of 90 participants, with 45 in the intervention group and 45 in the control group. In addition to routine care, patients in the intervention group will receive support for symptom management through a video-based educational intervention over a period of 8 weeks. Patients in the control group will receive the standard routine care provided at the study site. Data will be collected at three time points: baseline (T0), an interim follow-up (T1), and a final post-test (T2). The primary outcomes of the study are the level of self-efficacy regarding chemotherapy symptom management and quality of life. Secondary outcomes include the usability of the video-based educational intervention and instances of unplanned healthcare utilization (such as emergency department visits or unplanned hospital readmissions). Data collection will involve the use of a "Patient Information Form," the "Chemotherapy Symptom Management Self-Efficacy Scale for Breast Cancer," the "Functional Assessment of Cancer Therapy - Breast (FACT-B)," the "System Usability Scale," and a "Healthcare Utilization and Readmission Form" developed by the researcher. Data obtained from the study will be analyzed using the SPSS software package. It is anticipated that the video-based educational intervention will increase self-efficacy in symptom management among women diagnosed with breast cancer, improve their quality of life, and reduce the utilization of healthcare services, such as emergency department visits and hospital readmissions.

Studietype

Intervensjonell

Registrering (Antatt)

90

Fase

  • Ikke aktuelt

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studiesteder

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

  • Barn
  • Voksen
  • Eldre voksen

Tar imot friske frivillige

Ja

Kjønn som er kvalifisert for studier

Hunn

Beskrivelse

Inclusion Criteria:

  • Being 18 years of age or older,
  • Being able to read and write in Turkish,
  • Having no barriers to written or verbal communication,
  • Being newly diagnosed with breast cancer and being aware of the diagnosis,
  • Having received at least two cycles of chemotherapy,
  • Having access to an internet-enabled digital device (e.g., smartphone), either personally owned or shared with family members, and being able to use it actively,
  • Having an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-2.

Exclusion Criteria:

  • Patients who do not agree to participate in the study,
  • Patients participating in another study related to symptom management,
  • Patients with a history of diagnosed psychiatric disorders,
  • Patients with an Eastern Cooperative Oncology Group (ECOG) Performance Status of 3 or higher.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Støttende omsorg
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Dobbelt

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: INTERVENTION GROUP

In addition to routine care, patients in the intervention group will receive symptom management support over an 8-week period through a video-based educational intervention.

Participants in the intervention group will receive an 8-week video-based educational intervention in addition to standard care. The web-based platform will provide evidence-based educational videos on chemotherapy-related symptoms and symptom management. Participants will be directed to symptom-specific videos through a rule-based algorithm based on their self-reported symptoms. They will be asked to access the platform at least three times per week and will receive reminder messages twice weekly. Platform usage will be monitored, and post-intervention assessments will be conducted after the 8-week intervention.

Ingen inngripen: CONTROL GROUP

Patients in the control group will receive the routine care provided at the center where the study is being conducted.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Self-Efficacy Scale for Breast Cancer Related to Chemotherapy (SMSES-BC)
Tidsramme: Baseline (T0), Week 4 (T1), and Week 8 (T2).

Symptom management self-efficacy will be assessed using the Symptom Management Self-Efficacy Scale for Breast Cancer Related to Chemotherapy (SMSES-BC). Changes in self-efficacy scores will be evaluated across three assessment points.

Baseline (T0), Week 4 (T1), and Week 8 (T2).
Functional Assessment of Cancer Therapy-Breast (FACT-B)
Tidsramme: Baseline (T0), Week 4 (T1), and Week 8 (T2).

Quality of life will be assessed using the Functional Assessment of Cancer Therapy-Breast (FACT-B). Changes in quality-of-life scores will be evaluated across three assessment points.

Baseline (T0), Week 4 (T1), and Week 8 (T2).

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
System Usability Scale (SUS)
Tidsramme: At the end of the intervention (T2).

System usability will be assessed in the intervention group using the System Usability Scale (SUS) to evaluate participants' perceptions of the video-based educational platform.

At the end of the intervention (T2).
Hospital Readmissions
Tidsramme: Week 8 (T2), covering the previous 8 weeks.

Hospital readmissions will be assessed using a researcher-developed healthcare utilization form, including the occurrence, frequency, and duration of hospital readmissions during the 8-week study period.

Week 8 (T2), covering the previous 8 weeks.
Emergency Department Visits
Tidsramme: Week 8 (T2), covering the previous 8 weeks.

The number and reasons for emergency department visits during the 8-week study period will be assessed using a researcher-developed healthcare utilization form.

Week 8 (T2), covering the previous 8 weeks.
Unplanned Healthcare Visits
Tidsramme: Week 8 (T2), covering the previous 8 weeks.

The frequency and reasons for unplanned outpatient clinic visits and other healthcare facility visits will be assessed using a researcher-developed healthcare utilization form.

Week 8 (T2), covering the previous 8 weeks.
Treatment-Related Economic Burden
Tidsramme: Week 8 (T2), covering the previous 8 weeks.

Treatment-related economic burden will be assessed using a researcher-developed form to evaluate the financial burden associated with healthcare utilization during the study period.

Week 8 (T2), covering the previous 8 weeks.

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Etterforskere

  • Hovedetterforsker: Ümmühan Duman, Antalya Bilim University- ummuhan.duman@antalya.edu.tr

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Antatt)

1. desember 2026

Primær fullføring (Antatt)

1. februar 2027

Studiet fullført (Antatt)

1. mai 2027

Datoer for studieregistrering

Først innsendt

10. november 2026

Først innsendt som oppfylte QC-kriteriene

10. november 2026

Først lagt ut (Faktiske)

16. november 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

16. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

10. november 2026

Sist bekreftet

1. november 2026

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere